Bemnifosbuvir 是一种有效的具有口服活性的 HCV 病毒复制抑制剂。Bemnifosbuvir 有效抑制 SARS-CoV-2 (COVID-19) 感染 (EC₉₀=0.47 μM)。Bemnifosbuvir 具有全基因型抗病毒活性。

Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC 90 =0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity.

Solid

EC50: 5-28 nM (HCV)
EC90: 0.47 μM (SARS-CoV-2)

Bemnifosbuvir has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively.
In normal human airway epithelial cells, the concentration of Bemnifosbuvir required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells. has not independently confirmed the accuracy of these methods. They are for reference only.

When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir preferentially delivers high levels of AT-9010 in the liver in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

[1]. Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104.
[2]. Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8;AAC.02479-20.

In Vitro: DMSO : 100 mg/mL (171.96 mM; Need ultrasonic)配制储备液